推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
solid
藥物控制
regulated under CDSA - not available from Sigma-Aldrich Canada
顏色
yellow
溶解度
DMSO: ~18 mg/mL at 60 °C
SMILES 字串
CN1CCCCC1Cn2cc(C(=O)c3cc(ccc3I)[N+]([O-])=O)c4ccccc24
InChI
1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3
InChI 密鑰
ZUHIXXCLLBMBDW-UHFFFAOYSA-N
應用
(R,S)-AM1241 has been used as a cannabinoid CB2 agonist:
- to study its inhibitory effect on bone cancer-induced pain and bone loss[1]
- to study the effect of its interaction with 17βestradiol on proliferation activity in primary human osteoblasts[2]
- to evaluate the sites of CB2 mediated antinociception in vivo.[3]
生化／生理作用
AM1241 acts as an antinociceptive agent in several animal pain models.[4] It has a potential to delay disease progression in amyotrophic lateral sclerosis (ALS) mouse model.[5] Intrathecal, intravenous or intraperitoneal administration of AM1241 reduces hyperalgesia and allodynia in neuropathic rats.[6]
Selective CB2 cannabinoid receptor agonist
訊號詞
Danger
危險分類
Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis
Kim K, et al.
European Journal of Pharmacology, 542(1-3), 100-105 (2006)
The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats
de Carvalho CR, et al.
Epilepsy Research, 127(2), 160-167 (2016)
A synergistic interaction of 17-$\beta$-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts
Hojnik M, et al.
Biomedical Reports, 3(4), 554-558 (2015)
Elizabeth J Rahn et al.
Pharmacology, biochemistry, and behavior, 98(4), 493-502 (2011-03-09)
Cannabinoid CB(2) agonists produce antinociception without central nervous system (CNS) side-effects. This study was designed to characterize the pharmacological and antinociceptive profile of AM1710, a CB(2) agonist from the cannabilactone class of cannabinoids. AM1710 did not exhibit off-target activity at
Tannia Gutierrez et al.
Pain, 152(9), 1976-1987 (2011-05-10)
Drug self-administration methods were used to test the hypothesis that rats would self-medicate with a cannabinoid CB(2) agonist to attenuate a neuropathic pain state. Self-medication of the CB(2) agonist (R,S)-AM1241, but not vehicle, attenuated mechanical hypersensitivity produced by spared nerve
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
